{"id":"W4224035803","doi":"10.1158/1078-0432.ccr-21-3807","title":"Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Phases of clinical research; Clinical trial; Adverse effect; Immunotherapy; Expanded access; Hepatocellular cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002953943,0.000757337,0.001041725,0.0001831087,0.0002865307,0.0009842302,0.0005476168,0.0006228889,0.002725365],"category_scores_gemma":[0.002122384,0.000217721,0.0008862351,0.0003164209,0.0004410763,0.0008346739,0.0003638583,0.001668173,0.00072158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006991219,"about_ca_system_score_gemma":0.0009061132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004961494,"about_ca_topic_score_gemma":0.001544319,"domain_scores_codex":[0.9993383,0.0003547796,0.00006252392,0.00009438859,0.00008367239,0.00006632187],"domain_scores_gemma":[0.9984075,0.0003142765,0.000592289,0.0001959225,0.0001173228,0.0003726436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7839877,0.01657121,0.01825394,0.003004645,0.004816082,0.0003257338,0.0002827777,0.00249595,0.02860443,0.0003473996,0.01483312,0.126477],"study_design_scores_gemma":[0.6941214,0.203677,0.07098951,0.0003590179,0.003408811,0.001126251,0.0001339249,0.001705113,0.007044354,0.000500309,0.01685131,0.00008303456],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789593,0.009380599,0.0007082958,0.0008390943,0.0001217602,0.001494241,0.004862119,0.0001006626,0.003534092],"genre_scores_gemma":[0.9833778,0.003227831,0.0008886491,0.0009674086,0.0001832215,0.001215743,0.008753928,0.00002494648,0.001360385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002953943,"threshold_uncertainty_score":0.01562214,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.6690422892842558,"score_gpt":0.5552228490778292,"score_spread":0.1138194402064266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}